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Thank you for the opportunity to respond to Dr. Steven 
Moser's extensive letter-to-the-editor regarding the National 
Surgical Adjuvant Breast Project Breast Cancer Prevention Trial 
(NSABP Protocol P-1), also know as BCPT. 
Dr. Moser's letter is obviously written out of concern for the 
safety of participants in this trial and his concerns are deserving 
of a response. The NSABP P-1 (BCPT) study has been under 
discussion and development since 1984. All of the concerns 
mentioned by Dr. Moser have been fully evaluated by the FDA, 
the National Institutes of Health (NIH), the NSABP and many 
other groups. At a recent congressional hearing, the Director of 
the NIH, Dr. Bernadine Healy, described this study as one of the 
most thoroughly reviewed protocols ever at the National Cancer 
Institute (NC1)1• 
Let me address each of Dr. Moser's individual concerns 
about this trial. 
1. Level of Risk of the Participants: Contrary to the 
comment that premenopausal women eligible for this study 
"have a nil to slightly increased risk of breast cancer," women 
age 35 to 40 are required to have at least a 9-fold increased risk 
of breast cancer compared to a population of women without 
these risk factors before they can be considered for this trial. 
Most of these women are at an even higher than 9-fold increased 
risk, and many live in fear of dying from breast cancer. Most of 
these younger women have had at least 2 first-degree relatives 
(mother or sisters) diagnosed with breast cancer and some have 
seriously considered having bilateral prophylactic mastectomies 
in an attempt to prevent this dread disease. This is not a low-risk 
population and the fear of developing breast cancer is not a trivial 
concern in these young women's daily lives. 
The NSABP already has randomized more than 5,200 
women to tamoxifen or placebo in this trial as of December 1992. 
Only 4% of the women so far randomized have a risk of 
developing breast cancer equal to that of a 60-year-old woman. 
Over 70% of the women of all ages randomized to date have at 
least a 5-fold increased risk compared to that of a 60-year old 
woman and those who are premenopausal on the trial have much 
higher risks than this. 
2. Level of Reduction in Incidence of Contralateral 
Breast Cancers: Contrary to Dr. Moser's claim that this effect 
may be overestimated, more recent publications than those 
referenced by Dr. Moser representing 41,000 woman-years of 
tamoxifen treatment unequivocally demonstrate tamoxifen's 
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ability to reduce the incidence of recurrent ipsilateral and new 
contralateral breast cancer2•3.4. 
Furthermore, Peto' s recent meta-analysis of all randomized 
studies demonstrated a 39% odds reduction in contralateral 
breast tumors in patients taking tamoxifen4• 
3. Uterine Cancer Risk: It is not surprising that tamoxifen 
might increase the risk of uterine cancer due to its estrogen-agonist 
effect. The BCPT consent form states: 
"An increased risk of uterine cancer has 
been reported with the use of tamoxifen. 
Existing data from several large controlled 
clinical trials using 20mg tamoxifen shows 
that 9 out of 3,097 women on tamoxifen 
developed uterine cancer (0.3%) versus 4 
out of3,091 women not treated with tam-
oxifen (0.1% )." 
Seven randomized trials of tamoxifen all show the same 
relative rates of uterine cancer. It should be noted that 35% of the 
more than 5,000 women randomized so far on the BCPT have 
had hysterectomies. Thirty percent of the women under age 50 
who are on the BCPT already have had hysterectomies for benign 
uterine changes. For those who haven' thad hysterectomy, uterine 
cancer is rare under age 50. 
All women on the study are required to have a complete 
pelvic exam before entry on the trial and at least annually 
thereafter. The patients and their gynecologists are advised to 
immediately evaluate any abnormal uterine bleeding and 
endometrial biopsies are recommended for irregular bleeding. 
In the NSABP B-14 study, all of the uterine cancers that 
developed were diagnosed at Stage 0-1. 
4. Hepatic Cancer Risk: The 2liver cancers mentioned by 
Dr. Moser are the only 2 documented cases of liver cancer in the 
world in spite of 20 years of tamoxifen use in women with breast 
cancer. These 2 cases were from a Swedish trial using 40mg a day 
of tamoxifen (twice the currently used dose). Both of these cases 
occurred within 15 months of starting tamoxifen therapy. No 
other cases have been documented in spite of tracking thousands 
of women by the National Cancer Institute and the FDA. 
Although liver cancers have been produced in rats given 
tamoxifen, this has not been reproducible in any other species. A 
recent paper by Mani and Kupfef'i examining activation of 
tamoxifen to reactive metabolites in microsomes, implied that 
the human liver is apparently much less active than the livers of 
rats in activating tamoxifen to reactive intermediates. 
A recent publication by Han and Liehr 6 cited by Dr. Moser 
describes the formation of covalent DNA adducts in Sprague-
Dawley rat livers after high doses of tamoxifen. These adducts do 
not necessarily equate with DNA damage, which was not the 
subject of the investigation and no mutations were reported since 
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rats were sacrificed 4 hours after 1 to 6 
daily doses oftamoxifen (intraperitoneal 
tamoxifen 20mg/kg/day on days 1, 3, and 
6). The significance of this phenomenon 
has been the subject of research by Liehr 
et al since 19857•8• 
In several experimental animal 
systems, estrogen exposure previously 
has been observed to result in the 
formation ofDNA adducts. A wide range 
of estrogens can participate in the process, 
including natural endogenous estrogens. 
Adduct formation occurs between DNA 
and an unknown estrogen-induced DNA 
reactive compound. The experimental 
process is observed in liver and kidney. 
The details and significance of the 
reaction process remain a research issue. 
It is thought that these adducts can be 
stripped from DNA by normal repair 
processes. 
Two thousand women in 7 major 
adjuvant randomized clinical trials using 
20mg of tamoxifen have an overall 
median follow-up of 80 months, 
extending as long as 135 months for 
some groups. There have been no reported 
cases of liver cancer. A small group of 43 
patients at the University of Wisconsin 
continued rece1 vmg tamoxifen 
indefinitely following completion of 
adjuvant chemotherapy for early stage 
breast cancer. Follow-up currently 
exceeds 11 years with no reported cases 
of primary liver cancer9. 
Dr. Moser claims the tamoxifen 
breast cancer prevention trial does not 
call for specific liver function testing. 
This is not true. Liver function tests must 
be drawn on each patient before initiation 
of the trial and then at 3 months, 6 months, 
and then every 6 months for the duration 
of the study. 
Dr. Richard Love at the University 
of Wisconsin has studied adverse effects 
of tamoxifen for many years and believes 
that "the much discussed possibility of 
human primary liver neoplasia 
consequent to long-term tamoxifen 
treatment does not deserve listing" as an 
adverse effect10• 
The potential risk of hepatic cancer 
is mentioned in the BCPT consent form 
and is discussed with every patient. 
5. Risk of Pregnancy: All women 
on the trial are advised of the possibility 
of teratogenic risks of tarnoxifen to the 
fetus. All women are told they must avoid 
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pregnancy. Furthermore, new policies will require that all 
premenopausal women who could become pregnant must either 
have a negative pregnancy test at the time of initiating the trial or 
start the trial during their menstrual period. They are advised that 
tamoxifen can increase fertility and that adequate barrier 
contraceptives must be used. Again, it should be noted that 30% 
of the premenopausal women in this study have already had 
hysterectomies. 
If any woman should become pregnant while on the study, 
her medication will be immediately stopped and the code broken 
so that she will know if she was taking tamoxifen. 
Premenopausal women have been denied participation in 
clinical trials for many years because they might become pregnant. 
If they are denied participation in this trial, we will never know 
whether or not tamoxifen may benefit this large group of women 
at risk for breast cancer. TheN ational Cancer Institute agrees that 
to exclude premenopausal women is discriminatory. Furthermore, 
it is demeaning to assume they cannot responsibly avoid pregnancy 
when they have been advised of the risks. 
NSABP B-14 data suggests that tamoxifen may actually be 
more effective in preventing second breast cancers in 
premenopausal than in postmenopausal women. Furthermore 
the risks of deep venous thrombosis and endometrial cancer as an 
adverse effect of tamoxifen are rare in premenopausal patients. 
It would be wrong to exclude these women from the opportunity 
to participate. 
6. Risk of Promoting Hormone-Independent Tumors: 
The NSABP is aware of the data in rats showing development of 
rapidly growing hormone-independent tumors. In humans, we 
do not know if the breast cancers that are prevented are the 
hormone-dependent tumors, but we do know that multiple, large, 
randomized trials have shown benefit in disease-free survival 
and overall survival in patients with hormone receptor-negative, 
as well as hormone receptor-positive tumors, treated with 
tamoxifen. The role of tamoxifen in hormone-independent tumors 
currently is being evaluated in NSABP Protocol B-23 and other 
studies. 
Dr. Moser also comments that tamoxifen may simply delay 
the onset of hormone-sensitive tumors. This does not seem to be 
the case since continued follow-up of disease-free survival and 
overall survival in patients with breast cancer treated with 
tamoxifen shows the curves to continue to widen over time, 
showing prolonged benefit of tamoxifen even many years after 
it has been discontinued. 
7. Thrombophlebitis and Ocular Toxicity: Contrary to 
Dr. Moser's claim thatthese potential toxicities are not mentioned 
to patients, they both are included in the consent form. 
Thrombophlebitis very clearly is described as an adverse 
effect of tamoxifen. Women with a prior history of deep venous 
thrombosis or embolism and women taking coumadin or heparin 
are not eligible for the study. 
In the NSABP B-14 study, 3 of 1,414 women receiving 
placebo (0.2%) versus 18 of 1,403 women receiving tamoxifen 
(1.3%) developed deep venous thrombosis or embolism and 2 
deaths occurred. This is clearly stated in the consent. Most of the 
thromboembolic events were in women over age 60 and most of 
the affected women had a history of thromboembolic problems. 
These women are excluded from this study. Also it should be 
noted that these data are from women who all had cancer and are 
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known to be at increased risk of thrombosis. 
Rare ocular side-effects have been reported in patients 
receiving tamoxifen for breast cancer. These usually consist of 
retinopathy with fine, white, refractile opacities located 
superficially in the retina and concentrated especially in the 
macular region. Cases of optic neuritis also have beenreported11 • 
Because of the rarity of the event, the true incidence of 
retinopathy has not yet been estimated accurately. The NSABP 
currently is planning a cross-sectional investigation of a subset 
of patients from protocol B-14 in order to determine the 
prevalence of retinal and other ocular toxicities associated with 
long-term, low-dose tamoxifen administration. As of August 
1992, women with a history of macular degeneration of the 
retina are excluded from the BCPT. Tamoxifen is not known to 
accelerate pre-existing macular degeneration; however, the 
natural history of the disease is unpredictable. 11 
Participants are questioned on initiation of the study and at 
3 months, 6 months, and then at six-month intervals regarding 
subtle visual changes. More than a simple ophthalmoscopic 
exam is necessary to identify this rare ocular toxicity and, 
therefore, would be prohibitive to screen in every participant. 
Participants who do note any visual changes are referred for 
ophthalmologic exam. In the meantime, the cross-sectional study 
of the subset of NSABP B-14 patients will be forthcoming to 
identify the true risk level. 11 
8. Benefits of the Study: What Dr. Moser fails to note in his 
letter is the potential beneficial impact of this study which far 
outweighs any potential risks. All medications have some side 
effects. Cholesterol-reducing drugs and aspirin are other ex-
amples of medications that are widely used to treat patients 
prophylactically to reduce their risk of disease. According to 
personal comunication by Dr. Leslie Ford ofNCI, tamoxifen has 
been considered by the National Cancer Institute to be at least as 
safe as these drugs and as safe as routine vaccinations. 
It is hoped that tamoxifen in this prevention trial will be 
shown to reduce the incidence of invasive breast cancer by at least 
33% and the incidence of myocardial infarction by 20%. Studies 
also suggest that tamoxifen may delay or prevent bone density loss 
in postmenopausal women. 
I personally know of physicians already prescribing tamoxifen 
to healthy women at increased risk of breast cancer outside of a 
clinical trial. This is the real risk, and if this practice becomes more 
prevalent, we will never know the true relative risks and benefits 
of tamoxifen. Only through a well-controlled prospective study 
such as the BCPT can we address the risks Dr. Moser is concerned 
about. Only through such a trial can we identify those groups of 
women who have the greatest net benefit from tamoxifen therapy. 
The National Coalition for Cancer Research (NCCR) sup-
ports the BCPT and states "The NCCR believes" that the bad press 
about tamoxifen is "sensationalistic ... and represents a disservice 
to the women of this country ... There is ample scientific evidence 
to support the conduct of the study. Women deserve the right to 
choose whether or not to participate" 12• 
Tamoxifen is a relatively safe medication that potentially 
could make an enormous impact in saving women's lives. No 
medication is without side effects but the safest way to determine 
the relative benefits and risks is through a well-designed, con-
trolled, clinical trial. To exclude women under age 50 from this 
trial, or to prescribe tamoxifen off protocol, will eliminate the 
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possibility of ever determining the real relative risks and 
benefits in this age group. These are the women who may have 
the most to gain in absolute reduction of incidence of breast 
cancer. The known risks are well explained in the consent. How 
can we not do this study? If we do not complete this study, 
women will be treated with tarnoxifen empirically and the risks 
never will be really known. Also, they may not be followed as 
carefully as they are on the BCPT. 
The facts speak for themselves, and it must be concluded 
that the tarnoxifen breast cancer prevention trial is one of the 
most important, well designed and safest studies ever con-
ducted. 
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